Researchers compared vaccine coadministration with single-dose, sequential vaccination for the RSVPreF3 OA vaccine formulation in adults.
Commentary|Videos|June 19, 2026
Compounding, Peptides, and GLP-1s: Opportunities & Risks for Pharmacies in 2026
Lucas Morgan, Esq, and Dae Lee, PharmD, Esq, CPBS, present on the significant opportunities and regulatory risks surrounding compounded peptides and GLP-1 products in 2026.
Advertisement
Advertisement
With the shortage of commercially available drugs creating a massive opening for independent pharmacies to diversify their portfolios and tap into cash-based revenue, this growth is met with intense scrutiny from the FDA and state boards of pharmacy. This is especially prominent in the glucagon-like peptide-1 (GLP-1) and compounded peptide spaces.
Related to this article
A study of women aged 50 to 69 years found that thrombotic risk varied by route of administration, estradiol dose, and duration of use.
Despite technology fostering a new generation of health care delivery, experts believe rural health solutions should be sought elsewhere.
Medicaid coverage of obesity-labeled GLP-1 receptor agonists may substitute for, rather than simply add to, diabetes-labeled use, a new study finds.
Researchers outline individual peripheral arterial disease burden as well as the most at-risk patient populations and treatment recommendations.
Availability will vary by state, and a pharmacy professor says cost barriers can keep families from getting vaccinated.
Darren Mensch, PharmD, BCPS, BCACP, provides evidence-based nuance regarding the emergence of mRNA vaccine technology and health care’s understanding of it.
Study findings tie continuous glucose monitoring measures to elevated cardiovascular risk in adults without diabetes.
Advertisement
Advertisement